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ABSTRACT 
!
! Chronic mental stress is emerging as a cardiovascular disease (CVD) risk factor; 
however, the underlying physiological mechanisms to explain how chronic mental stress may be 
causing CVD are still under investigation. Previous literature has demonstrated that chronic 
mental stress can induce endothelial dysfunction, which is a well-known independent risk factor 
for CVD. The purpose of this study was to further investigate the underlying pathophysiological 
mechanisms that may be contributing to this endothelial dysfunction, in the normotensive 
Wistar-Kyoto (WKY) and Spontaneously Hypertensive (SHR) rat models. A chronic mental 
stress protocol, known as the Unpredictable Chronic Mild Stress (UCMS) protocol, was used to 
induce chronic mental stress in the animals in order to determine its effects on endothelial 
function. Animals were divided up into four groups: WKY CON, WKY UCMS, SHR CON, and 
SHR UCMS. To test the efficacy of the UCMS protocol, behavioural tests were performed to 
confirm the presence of mental stress in the animals in the UCMS groups compared to the 
control groups (Coat status: WKY: p<0.0001, SHR: p<0.0006; Splash test (Grooming 
Frequency): WKY: p=0.5581, SHR: p=0.0050). Unexpectedly, compared to WKY CON 
endothelium-dependent, acetylcholine (ACh)-stimulated vasocontraction (Maximum Amp 
(MAX): 27.25±5.95, Area Under the Curve (AUC): 54.22±10.98, EC50: 2.58±0.79), UCMS was 
found to significantly attenuate endothelium-dependent, ACh-stimulated MAX (11.86±2.91; 
p=0.043) and AUC (24.87±5.43; p=0.037), but not EC50 (2.48±1.20; p=0.913). Likewise, 
compared to SHR CON endothelium-dependent, ACh-stimulated vasocontraction (MAX: 
48.5±9.0, AUC: 84.3±15.4, EC50: 2.44±0.70), UCMS was found to attenuate endothelium-
dependent, ACh-stimulated MAX (33.40±6.51; p=0.083), AUC (65.42±12.76; p=0.170), and 
EC50 (1.62±0.43; p=0.202), however this attenuation did not reach significance. Furthermore, 
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compared to WKY CON endothelium-dependent, ACh-stimulated vasorelaxation MAX: 
92.43±3.08, AUC: 300.6±17.84, EC50: 95.25±32.16), UCMS was found to significantly augment 
endothelium-dependent, ACh-stimulated AUC (349.9±13.42; p=0.040), and insignificantly 
augment endothelium-dependent, ACh-stimulated MAX (101.0±1.35; p=0.241) and EC50 
(41.0±8.44; p=0.120). Likewise, compared to SHR CON endothelium-dependent, ACh-
stimulated vasorelaxation (MAX: 83.81±3.19, AUC: 282.4±12.19, EC50: 69.41±25.53), UCMS 
was found to augment endothelium-dependent, ACh-stimulated MAX (88.65±2.63; p=0.250), 
AUC (287.0±11.09; p=0.781), and EC50 (87.83±32.3; p=0.669), however this augmentation did 
not reach significance. Dose-dependent response curves to sodium nitroprusside (SNP) and 
U46619 were similar across all groups, suggesting that the attenuated vasocontraction and 
enhanced vasorelaxation was not due to UCMS having an effect on vascular smooth muscle 
(VSM) sensitivity, but is more likely due to a reduction in endothelium-derived contracting 
factor (EDCF) production/bioavailability and/or an increase in endothelium-derived relaxing 
factor (EDRF) production/bioavailability. 
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1.0 Introduction 
This thesis focused on the effect of chronic mental stress on endothelium-dependent 
vasomotor function in the common carotid artery (CCA) of hypertensive and normotensive rats. 
The following offers an introduction to the concepts required to better understand the purpose 
and objectives of this study. 
 
1.1 Structure and Related Functions of Blood Vessels 
 Most blood vessels are comprised of three layers including the adventitia, the media, and 
the intima (1). Of particular importance, are the several layers of vascular smooth muscle (VSM) 
cells within the media and the single layer of endothelial cells that line the innermost surface of 
blood vessels, composing the intima (2, 3, 4).  
The endothelium not only functions to produce a barrier between the lumen and outer 
layers of the blood vessel, it also plays a crucial role in regulating several vascular homeostatic 
processes, including: platelet aggregation, leukocyte adhesion, inflammatory processes, VSM 
proliferation, and vascular tone (Figure 1). The endothelium produces several endothelium-
derived substances (see Endothelium-Derived Relaxing and Contracting Factors, below), which 
assist in the regulation of these vascular homeostatic processes (5, 6, 7, 8, 9, 10). The main 
function of the VSM is to contract and relax in a graded manner, thereby regulating vascular 
tone. Precise control of vascular tone plays a crucial role in regulating blood flow and pressure. 
A number of endothelium-derived relaxing factors (EDRFs) and endothelium-derived 
contracting factors (EDCFs) contribute to the regulation of VSM function and vascular tone.  
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1.2 Vascular Tone 
 Vascular tone refers to the extent of vasocontraction that is present in a blood vessel. 
Most blood vessels, particularly small arteries and arterioles, exhibit some level of 
vasocontraction under basal physiological conditions and therefore exhibit some degree of 
vascular tone in their basal state (11). From this point of partial contraction, the smooth muscle 
surrounding the vessel can either contract further or relax, resulting in graded vasoconstrictory or 
vasodilatory responses, respectively. These responses maintain homeostatic blood flow and 
blood pressure in response to disturbances. The precise control of vascular tone is regulated 
through a healthy balance of vasodilator and vasoconstrictor substances (2, 6, 7, 8, 9, 10, 12, 13), 
many of them working via paracrine and endocrine signalling mechanisms, often involving the 
endothelium (5, 6, 12, 13, 14).  
 
1.3 The Endothelium 
The endothelium plays a crucial role in maintaining vascular tone and overall health of 
the blood vessel by secreting several diffusible substances; namely, vasodilators and 
vasoconstrictors, known as EDRFs and EDCFs, respectively (6, 7, 15, 16). The relative balance 
of EDRF and EDCF production and activity significantly contributes to the dynamic regulation 
of vascular tone and overall health of the blood vessel (Figure 1) (7).  
 
1.3.1 Endothelium-Derived Relaxing and Contracting Factors 
A powerful EDRF is nitric oxide (NO), which has the ability to diffuse across the cell 
membrane into VSM cells and induce relaxation of a blood vessel (17). Other EDRFs typically 
include endothelium-derived hyperpolarizing factors (EDHF) and cyclooxygenase (COX)-
derived prostacyclin (PGI2) (4, 16, 17). Importantly, the extent to which NO, EDHFs, or PGI2 
! L!
contributes to endothelium-dependent vasorelaxation varies depending on the vascular bed, size 
of the blood vessel as well as the species and strain of animal being investigated (18). 
Some major EDCFs are also COX-derived, meaning they are produced in the endothelial 
cell via a COX-mediated reaction from arachidonic acid (AA) (16, 19). They include 
thromboxane A2 (TXA2), prostaglandin F2-alpha (PGF2!), prostaglandin D2 (PGD2), and 
prostaglandin E2 (PGE2); all of which are collectively known as prostanoids (4, 17). In addition, 
major non-COX-mediated EDCFs include endothelin-1 (ET-1) and angiotensin II.   
These EDRFs and EDCFs are continually and simultaneously being secreted by the 
endothelium, producing a delicate balance of vasodilator and vasoconstrictor substances (13, 16, 
17). Subsequently, these substances variously contribute to the regulation of vascular 
homeostatic processes including platelet aggregation, leukocyte adhesion, thrombosis, 
inflammation, VSM proliferation, and/or they can diffuse directly into the VSM or bind to and 
stimulate receptors on the VSM cell membrane to control vascular tone (Figure 1) (15).  
 
                        
Figure 1: Healthy endothelium-dependent regulation of vascular homeostatic processes. 
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1.3.2 Endothelial Control of Vascular Health 
 In larger arteries (e.g., aorta and CCA), the primary function of EDRFs and EDCFs is in 
regulating the overall health of the vessel. While EDRFs are involved in preventing platelet 
aggregation, leukocyte adhesion, thrombosis, inflammation, and VSM proliferation within the 
blood vessel, EDCFs can counteract these effects by promoting platelet aggregation, leukocyte 
adhesion, thrombosis, inflammation, and VSM proliferation (15, 20, 21, 22). For example, PGI2 
can bind to prostacyclin IP receptors that are located on platelet cells and inhibit platelet 
aggregation (23, 24), whereas TXA2 can bind to thromboxane-prostanoid (TP) receptors, also 
located on platelets cells, and activate platelet aggregation (25).  
As long as a “healthy” balance of EDRF and EDCF production and activity exists within 
the blood vessel, a healthy anti-thrombotic/anti-inflammatory/anti-oxidative/anti-proliferative 
environment will be maintained and the overall health of the blood vessel will be preserved 
(Figure 1).  
 
1.3.3 Endothelial Vasomotor Function 
In smaller arteries and arterioles, the primary function of EDRFs and EDCFs is to aid in 
vasomotor functional responses through regulation of vascular tone. Vasodilation and/or 
vasoconstriction can occur in response to three types of biophysical stimuli: mechanical, 
electrochemical, and/or receptor-mediated (1, 17, 26, 27, 28, 29, 30). Each of these stimuli can 
act on the endothelium or the VSM, ultimately leading to a change in intracellular calcium (Ca2+) 
within the endothelial and/or VSM cell triggering a cascade of events that results in either 
vasodilation or vasoconstriction (16, 30). Stimulation of the endothelium, for example, leads to 
an increase in intracellular Ca2+ resulting in the activation of several enzymes that ultimately 
produce EDRFs and EDCFs. These EDRFs and/or EDCFs can then act on the underlying VSM 
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cells to cause either relaxation, and resultant vasodilation, or increased contraction, and resultant 
vasoconstriction, which is necessary in the regulation of vascular tone (6, 7, 8, 9, 16, 30). 
It is important to note, however, that a single vasoactive substance has the capacity to 
bind to and activate a variety of receptor types. Furthermore, these different receptor types are 
often connected to varied subcellular signalling mechanisms that often have opposing effects on 
one another. For example, while ET-1 tends to have a higher affinity for endothelin receptor type 
A (ETA), which acts through contractile subcellular signalling mechanisms, it can also bind to 
endothelin receptor type B1 (ETB1) to elicit VSM relaxation (1). Similarly, PGI2 most often 
elicits vasorelaxation because it has a higher affinity for IP receptors, but in some cases will 
activate the TP receptor and elicit vasocontraction (31, 32, 33) (see Endothelial Dysfunction and 
Vascular Disease). Therefore, the overall vascular tone will not only be influenced by which 
vasoactive substances are being produced, but also by whether these vasoactive substances act on 
receptors that are connected to contractile or dilatory subcellular signalling mechanisms. 
Moreover, the affinity for a particular receptor by a vasoactive substance may be strongly 
influenced by the overall state of the blood vessel (e.g., health of the endothelium) (34, 35).  
 
1.3.4 Endothelial Dysfunction and Vascular Disease   
Endothelial dysfunction can be defined as an imbalance in EDRF and EDCF 
production/activity impairing the regulation of vascular homeostasis (e.g., vascular tone) (15). 
Importantly, this imbalance can be the result of reduced EDRF activity, increased EDCF activity, 
or in some cases, a combination of the two (6, 16). An imbalance in these vasoactive substances 
predisposes blood vessels to the pro-constrictory/pro-thrombotic/pro-inflammatory/proliferative 
state that is associated with so many cardiovascular disease (CVD) states, including 
atherosclerosis and hypertension (9, 30, 36). For example, endothelial dysfunction has been 
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demonstrated in a frequently studied animal model of hypertension, known as the Spontaneously 
Hypertensive (SHR) rat, which was shown to be in part due to over-active EDCF activity (31, 
32, 37, 38, 39). It was further determined that dysfunctional IP receptors on the VSM wall 
further contributes to the over-active EDCF activity and thereby further contributes to the 
resulting endothelial dysfunction seen in this model of hypertension (31, 32, 39). Like many 
endothelium-derived vasoactive substances, PGI2 can bind to multiple receptor types. In healthy 
vasculature, PGI2 has a higher affinity for IP receptors, which are connected to dilatory 
subcellular signalling mechanisms that elicit vasorelaxation when activated (31, 32, 33). In SHR 
rats, however, an increase in dysfunctional IP receptors instead results in activation of TP 
receptors by PGI2 resulting in the activation of contractile subcellular signalling mechanisms, 
and vasocontraction (31, 32, 33). As a result, PGI2 becomes a potent vasoconstrictor in SHR rats, 
resulting in over-active EDCF activity and further promoting a pro-constrictory state and, 
therefore, endothelial dysfunction (16, 31, 32, 33).  
 
1.3.5 Measuring Endothelial Function 
Since the discovery of the importance of endothelial health, many techniques have been 
developed over the years to assess endothelial function in humans and a variety of animal 
models, through both in-vivo and in-vitro methods. 
 While it is possible to directly measure endothelial function in human coronary arteries, 
this technique is highly invasive and considered very high risk for the patient (1, 15, 40). For 
these reasons, endothelial function in humans is most commonly measured in the peripheral 
circulation by analyzing the blood vessel’s response to a mechanical stimulus known as shear 
stress, which is the result of an increase in blood flow. An increase in blood flow and resultant 
shear stress on the blood vessel can stimulate the endothelium to release NO; this collective 
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process is known as flow-mediated dilation (1, 15). Flow-mediated dilation is often measured in 
the brachial artery using Doppler ultrasound, allowing for a non-invasive measure of NO-
mediated endothelium-dependent vasorelaxation (15). This is of importance because impairment 
in endothelium-dependent vasorelaxation is considered a hallmark of endothelial dysfunction, 
which is an independent predictor of cardiovascular events (e.g., myocardial infarction) (41, 42).    
Animal models allow for the assessment of endothelial health through direct assessment 
of endothelium-dependent vasorelaxation and endothelium-dependent vasocontraction. This can 
be accomplished, in-vitro, by isolating a segment of the artery of interest followed by vascular 
myography (see Vasomotor Activity in the Methods section, below) (39). The advantage to 
studying endothelial function in-vitro (e.g., using vascular myography), is that the environment 
in which the artery segment is being investigated can be easily controlled and manipulated (43). 
Furthermore, physiological/mechanistic adaptations made in vivo, as a result of any 
intervention/perturbation, can be pharmaco-dissected in vitro (39, 43). This is a commonly used 
method for better understanding the physiological adaptations to any intervention/perturbation on 
a mechanistic level (43). 
 
1.4 Cardiovascular Disease and Associated Risk Factors 
 Cardiovascular disease (CVD) is a class of chronic conditions involving the heart and/or 
blood vessels that develop over time as the result of the presence of and exposure to non-
modifiable and modifiable risk factors (40). 
 
1.4.1 Modifiable and Non-modifiable CVD Risk Factors 
Non-modifiable risk factors, such as age and genetics (e.g., sex, race, family history), 
cannot be altered by an individual’s choices, actions, or behaviours. Conversely, an important 
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distinguishing feature of modifiable (non-genetic) risk factors is that they can be changed (i.e., 
modified), as they are sensitive to an individual’s choices, actions, and behaviours. Traditional 
modifiable risk factors include diet, exercise, and tobacco use (44). Much research currently 
exists describing the influences of these factors on vascular function. Notably, a less thought-of, 
yet equally modifiable risk factor to consider is chronic mental stress.  
There is evidence to suggest that psychosocial factors (e.g., anxiety, depression, and 
chronic life stress) significantly increase the risk of CVD (45, 46, 47, 48). This may, in part, be 
due to the unhealthy decision-making (e.g., smoking, unhealthy diet, lack of exercise) that often 
accompanies negative psychosocial factors, including chronic mental stress (45, 49, 50). 
Importantly, however, even independent of the unhealthy decision-making, the negative 
psychosocial stress itself has been shown to be associated with CVD and, more specifically, 
endothelial dysfunction (48, 51).  
 
1.5 Chronic Mental Stress 
1.5.1 Chronic Mental Stress as a Modifiable CVD Risk Factor 
Chronic mental stress has long been associated with adverse health outcomes, including 
CVD, but is often ignored when considering the risk factors that can be modified by an 
individual’s behaviours (45, 46, 52, 53, 54). A surge in interest to better understand the 
physiological outcomes of psychological factors, such as chronic mental stress, has become 
apparent over the past decade (55, 56). However, much of the physiology demonstrating how 
chronic mental stress can affect (patho)physiological processes (e.g., endothelial function) 
remains to be investigated (56). 
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1.5.2 Unpredictable Chronic Mild Stress (UCMS) Protocol 
Several animal models of chronic mental stress, including the Crowded Housing Stress 
model, the Chronic Behavioural Stress model, and the Unpredictable Chronic Mild Stress 
(UCMS) protocol, have been developed for investigating behavioural and physiological 
outcomes of chronic mental stress (56, 57, 58, 59, 60, 61). In recent years these chronic mental 
stress models have been used to better understand the underlying mechanisms involved in 
psychological stress-induced CVD (56, 57, 58, 59, 60, 61). To date, the UCMS protocol is the 
most validated model for studying the (patho)physiological outcomes of chronic mental stress 
(61, 62). This protocol involves intermittently exposing rats to one or more of the “mild” 
stressors, chosen by the investigators, in a repetitive but unpredictable manner (See Appendix I 
for the stress schedule used in this study) (56). Examples of mild stressors commonly used by 
investigators using the UCMS model include tilting the rats’ cage, altering the rats’ light/dark 
cycle, and removing the rats’ bedding from their cage (63, 64, 65, 66, 67). While the protocol 
varies slightly from study-to-study, a total of approximately six stressors are generally chosen for 
each of the UCMS protocols. Then, from this list of stressors, approximately three stressors are 
randomly selected and applied to the rats each day. The time at which each stressor is applied, as 
well as the duration that each stressor will last, is also randomized each day. This randomization 
allows the investigator to apply each stressor to the rodents in an unpredictable manner and avoid 
adaptation by the rodents to these stressors (56). 
 
1.6 Chronic Mental Stress and Endothelial Dysfunction 
Several investigators have used the UCMS protocol to investigate a causal link between 
chronic mental stress and CVD (63, 64, 65, 66, 67). For example, numerous studies that have 
utilized the UCMS protocol have reported induction of vascular dysfunction in rodents, 
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suggesting that chronic mental stress is physiologically linked to the resulting vascular 
dysfunction (65, 66, 67, 68, 69). More specifically, investigators have been studying the 
endothelial dysfunction resulting from the chronic mental stress associated with the UCMS 
protocol (65, 66, 67).  
 
1.6.1 Chronic Mental Stress and Impaired Endothelium-Dependent Vasorelaxation 
To date, studies of endothelial dysfunction in UCMS have focused on reduced 
endothelium-dependent vasorelaxation, and the possible involvement of NO in this impairment 
(65, 68, 69, 70, 71). Previous literature has demonstrated that UCMS impairs endothelium-
dependent vasorelaxation in aorta of Wistar rats and Balb/cJ mice (65, 66, 68, 69). A significant 
reduction in endothelial nitric oxide synthase (eNOS) expression as a result of the UCMS 
protocol has also been demonstrated in Aorta of Wistar rats (68, 69). Moreover, vasorelaxation 
in response to sodium nitroprusside (SNP), an external source of NO, has been shown to not be 
impaired after the UCMS protocol in these animals (65, 69). These data suggest that the 
impairment in endothelium-dependent vasorelaxation is, at least in part, caused by a significant 
reduction in production of NO, rather than a decreased sensitivity of the VSM to the NO.  
Impairment in a blood vessel’s ability to relax, however, may not only be due to under-
active EDRFs, but may also be due to over-active signalling of COX-mediated EDCFs, or some 
combination of both (6, 16). It is therefore necessary to consider not only the bioavailability and 
VSM-sensitivity of NO and other EDRFs (i.e., prostaglandins, EDHFs) but also the potential 
changes in EDCFs when investigating endothelial responses in any stress adaptation model, 
including UCMS. 
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1.6.2 Chronic Mental Stress and Augmented Endothelium-Dependent Vasocontraction 
 No literature currently exists whereby the effects of UCMS on endothelium-dependent 
vasocontraction and the contributing EDCF activity have been specifically investigated. A study 
by Fuchs et al., however, could suggest that EDCF activity becomes augmented, which may 
contribute to an enhancement in endothelium-dependent vasocontraction (59). Fuchs et al. used 
“chronic behavioural stress” to induced impairment in endothelium-dependent vasorelaxation in 
Borderline Hypertensive Rats (BHR), a first-generation cross between SHR and wistar-kyoto 
(WKY) rats (59). Rather than using the UCMS protocol, the investigators used air-jets to blow 
compressed air on young (3 mo) and old (18 mo) BHR for 2 hours/day and the protocol lasted 
for a total of ten days. In this experiment, the “chronic behavioural stress” was sufficient to 
significantly impair acetylcholine (ACh)-induced, endothelium-dependent vasorelaxation in 
coronary arteries of the old stressed rats compared to the old control rats. Interestingly, 
preincubation with the nitric oxide synthase (NOS) inhibitor L-NG-nitroarginine methyl ester (L-
name) did not eliminate the impairment in relaxation; however, preincubation with the COX 
inhibitor indomethacin (Indo) did (59). While Fuchs et al. suggest that the impairment in ACh-
induced endothelium-dependent vasorelaxation in the old stressed rats may in part be due to an 
increase in endothelium-dependent vasoconstrictor prostaglandins, which may counteract the 
endothelium-dependent vasodilators, the study did not specifically investigate COX-mediated 
EDCF activity. It can therefore be hypothesized that if endothelium-dependent vasocontractile 
activity would have been specifically investigated in this study, the investigators may have found 
an augmentation in endothelium-dependent, COX-mediated vasocontraction in the old stressed 
rats compared to the old control rats. 
 
 
! JK!
1.7 Animal Model  
 In this study, the effects of UCMS were measured and compared within and between 
normotensive Wistar-Kyoto (WKY) and Spontaneously Hypertensive (SHR) rats.  
 In 1951, Wistar rats were sent from the Wistar Laboratory in the United States to Kyoto 
University in Japan where the first generation of WKY rats was bred (72). The SHR rat strain 
was later developed by breeding several generations of spontaneously hypertensive WKY rats 
(72). Today, the SHR rat is the most commonly studied animal model of essential hypertension, 
and WKY rats are often used as the normotensive control strain to which findings in SHR rats 
are compared against (73).  
 Endothelial dysfunction, as characterized by reduced endothelial-dependent 
vasorelaxation and/or enhanced endothelium-dependent vasocontraction, has been demonstrated 
in arteries from SHR rats compared to WKY (39). These data suggest that the underlying cause 
of hypertension in SHR may also be associated with the endothelial dysfunction that is present in 
this strain of rat.  
 Early studies investigating the cause of endothelial dysfunction in SHR rats suggested 
that the endothelium could not produce and/or release a sufficient amount of EDRFs, most 
notably NO, to sustain healthy vascular tone (7). However, more recent literature investigating 
impaired endothelium-dependent vasorelaxation in SHR CCA has shown that preincubation with 
the COX-inhibitor indomethacin can reverse the impairment in endothelial-dependent 
vasorelaxation (39). These data suggest that the reduced endothelium-dependent vasorelaxation 
in CCA of SHR rats is, at least in part, COX-mediated. Furthermore, this reduced endothelium-
dependent vasorelaxation has also been shown to be associated with a significant increase in 
endothelial-dependent vasocontraction (39).  
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 Importantly, the majority of studies investigating endothelial dysfunction focuses on the 
impairment in endothelium-dependent vasorelaxation and do not specifically investigate whether 
an enhancement in endothelium-vasocontraction is present (39, 74, 75, 76). Since it is now 
known that endothelial dysfunction can be also be caused by an increase in EDCF 
activity/bioavailability, and not only a reduction in EDRF activity/bioavailability, it is important 
that investigators specifically investigate EDCF activity by studying endothelium-dependent 
vasocontraction (28, 77, 78, 79). Therefore, in the current study, SHR animals were used because 
both a reduction in EDRF activity as well as an increase in EDCF activity have been shown to 
contribute to the endothelial dysfunction present in this animal model (7, 31, 32, 37, 38, 39). 
Furthermore, the mechanisms underlying this endothelial dysfunction have been well defined. 
Additionally, WKY animals were used in the current study since they are often the control strain 
to which findings in SHR animals are compared against (73).  
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2.0 Purpose 
 The purpose of this thesis was to further investigate the underlying pathophysiological 
mechanisms contributing to endothelial dysfunction associated with chronic mental stress in a rat 
model. Whether the endothelial dysfunction is a result of a reduction in EDRF activity, an 
augmentation of EDCF activity, or some combination of the two was further analyzed in this 
thesis. More specifically, we examined: 
 
1. The effect of UCMS on endothelium-dependent vasorelaxation in the CCA of WKY 
and SHR rats. 
2. The effect of UCMS on endothelium-dependent, COX-mediated vasocontraction in 
the CCA of WKY and SHR rats. 
3. Whether the impairments of endothelium-dependent vasorelaxation and/or 
endothelium-dependent vasocontraction were greater or less in the SHR UCMS group 
compared to the WKY UCMS group, compared to their respective strain control 
(CON) group. 
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3.0 Hypotheses  
3.1 Hypothesis 1 
Hypothesis 1: Compared to their respective controls, UCMS will impair endothelium-
dependent vasorelaxation in both WKY and SHR  
The majority of previous studies that have investigated the endothelial dysfunction 
associated with chronic mental stress have demonstrated that endothelium-dependent 
vasorelaxation is significantly impaired in the stress groups compared to their respective control 
groups (65, 66, 68, 69, 70, 71). Furthermore, some studies have demonstrated that the UCMS 
protocol, specifically, impaired endothelium-dependent vasorelaxation in aorta of Wistar rats and 
Balb/cJ mice (65, 66, 68, 69).  
 
3.2 Hypothesis 2 
Hypothesis 2: Compared to their respective controls, UCMS will augment endothelium-
dependent, COX-mediated vasocontraction in both WKY and SHR 
As mentioned previously, Fuchs et al. demonstrated that chronic behavioural stress 
impaired endothelium-dependent vasorelaxation that was reversed by indomethacin but not NO, 
suggesting that the impairment was, at least partly, due to increased EDCF activity (59). 
Furthermore, a study by Stanley et al. found that the vascular production of COX-mediated 
vasoconstrictor, TXA2, was significantly greater in Balb/cJ mice after UCMS compared to 
control mice (65). Together, these data suggest that an increase in COX-mediated EDCF activity 
may contribute to the impairment in vasorelaxation associated with the chronic stress. 
Furthermore, it suggests that, if specifically investigated, increased EDCF activity may also 
cause enhanced endothelium-dependent vasocontraction. 
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Based on these data, it is hypothesized that the UCMS protocol will significantly enhance 
endothelium-dependent vasocontraction in both WKY and SHR rats. Furthermore, it is 
hypothesized that this augmentation will be the result of an increase in COX-mediated EDCF 
production/activity, rather than an increased sensitivity of the VSM (i.e., TP receptor sensitivity) 
to the EDCFs. 
 
3.3 Hypothesis 3 
Hypothesis 3: The UCMS-induced impairment in endothelium-dependent vasorelaxation 
(Figure 2A) and the UCMS-induced augmentation in endothelium-dependent 
vasocontraction (Figure 2B) will be greater in WKY compared to SHR. 
Previous literature has established that endothelium-dependent vasorelaxation is 
significantly attenuated in arteries from SHR compared to WKY and, furthermore, that 
endothelium-dependent vasocontraction is significantly augmented in arteries from SHR 
compared to WKY (37, 38, 39).  
Based on these findings, it is hypothesized that the UCMS protocol will exaggerate the, 
already existing, impairments in vasomotor function in the SHR rats overall resulting in 
significantly reduced endothelium-dependent vasorelaxation and significantly greater 
endothelium-dependent vasocontraction in SHR compared to WKY (i.e., significantly greater 
absolute impairment in vasomotor function in the SHR UCMS group compared to the WKY 
UCMS group). 
In contrast, because little impairment in vasomotor function exists in arteries of control 
WKY rats, unlike in SHR, it is reasonable to assume that a larger capacity for impairment in 
vasomotor activity exists in the WKY rats compared to the SHR rats. Therefore, it is 
hypothesized that a greater relative/overall change in impairment in vasomotor function (i.e., 
! JP!
reduced endothelium-dependent vasorelaxation and augmented endothelium-dependent 
vasocontraction) will be observed between the WKY UCMS and control groups compared to the 
relative impairment between the SHR UCMS and control groups. These data would suggest that 
chronic mental stress has a greater relative effect on endothelial function in normotensive WKY 
rats compared to hypertensive SHR rats. 
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Figure 2: Hypothesized UCMS-induced impairment in endothelium-dependent vasorelaxation and 
vasocontraction. The UCMS-induced impairment in endothelium-dependent vasorelaxation (A) and the UCMS-
induced augmentation in endothelium-dependent vasocontraction (B) will be greater in WKY compared to SHR. 
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4.0 Materials and Methods 
4.1 Animal Model 
Male WKY (n=24) and SHR (n=24) aged 30-40 weeks were obtained from the 
University of Waterloo breeding colony. Animals were housed two per cage in the Central 
Animal Facility (CAF) at the University of Waterloo, and had access to standard chow (Harlan 
Laboratories) and tap water ad libitum. Food and water intake of all animals was monitored 
throughout the study.   
Animals were divided into four groups including two control (CON) groups (n=12 WKY; 
n=12 SHR) and two chronic mental stress (UCMS) groups (n=12 WKY; n=12 SHR). All control 
animals were housed in a separate quiet room from the UCMS group. After six weeks under 
either condition, rats!were anesthetized via an intraperitoneal injection using Sodium 
Pentobarbital at a dose of 45 mg/kg of body weight (BW). Once deemed adequately anesthetized 
(i.e., no pain response with toe pinch test), the rat was sacrificed via exsanguination for 
vasomotor function testing (see 4.4 Vasomotor Activity) and biochemical analyses (see 4.5 
Biochemical Analyses).  
 
4.2 Unpredictable Chronic Mild Stress 
Animals were stressed 3 times/day for a total of six weeks and were stressed, on average, 
58% of the time in a 24-hour period. The same stressor was not used more than once per day or 
in succession (i.e., the last stressor one day was never the first stressor the following day) to 
avoid any adaptation by the animals to the stressor.  
 The stressors used in this experiment included (1) removal of bedding: bedding was 
removed from the cage (65, 66, 67, 70, 71), (2) damp bedding: Enough water was added to the 
cage to cause damp but not fully saturated bedding (i.e., no pools of water were present; ~75 mL 
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water per 1 cup of bedding) (65, 66, 67, 68, 69, 70, 71, 80, 81), (3) altered light/dark cycle: the 
light/dark cycle was interrupted by turning the lights on and off every 30 minutes (65, 67),  (4) 
cage tilting: the cage was tilted 45o (65, 66, 67, 70, 71), (5) predator odour: coyote urine was 
placed near, but outside, the cages, and (6) predator sounds: a recording of cat growling/hissing 
was placed in the room (65, 67). For ethical reasons, the stressors did not include food and/or 
water deprivation.  
 
4.3 Efficacy Measures of UCMS Protocol 
 As described in previous literature using the UCMS protocol, behavioural tests were 
completed regularly during the UCMS protocol to test the efficacy of the protocol itself (65, 66, 
67, 70, 71, 82, 83). The behavioural tests included the splash test and monitoring coat status, as 
described in detail below. Furthermore, the same behavioural tests were also regularly completed 
in the control groups to allow for comparison of the chronic stress in the rats in the UCMS group 
compared to the rats in the control group.  
 
4.3.1 Coat Status 
 Consistent with past studies, coat status was evaluated weekly throughout the duration of 
the protocol (65, 66, 67, 71). Eight different body parts (i.e., head, neck, dorsal coat, ventral coat, 
tail, forelimb, hind limb, and genital region) were individually assessed and assigned a score of 
either 0 or 1 depending on whether the coat was clean or dirty, as described in previous 
literature, and a total cumulative score was obtained for each rat by calculating the sum of these 
eight scores (65, 66, 67, 71). The Animal Care Technician provided guidelines for what was 
considered as a “clean” or “dirty” coat.  
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Due to the subjective nature of the test, one person determined the coat status each week 
for the duration of the protocol, to ensure consistency each week. Furthermore, a second 
observer rated the coats independently but at the same time as the primary rater 25% of the time 
to determine the degree of agreement between the two raters.  
 
4.3.2 Splash Test 
 The dorsal coat of the rats were sprayed, or “splashed”, twice with a 10% sucrose 
solution, as described in previous literature (65, 66, 67, 70). The viscosity of the sucrose solution 
was sufficient to dirty the coat and initiate grooming. A lack of grooming is considered a sign of 
depression in rodents. Therefore, reduced grooming activity was indicative of depressive 
behaviour in the rat (65, 66, 67, 70).  
The amount of time spent grooming, defined as licking and/or scratching, during the first 
five minutes after being sprayed was recorded. More specifically, the number of times the rat 
engaged in grooming (i.e., frequency) and the idle time between the spray and the initiation of 
grooming (i.e., latency time) was observed, recorded, and compared between animals (65, 66, 
67, 70). 
 
4.4 Vasomotor Activity 
Both the left and right CCAs were extracted from anaesthetized animals for the 
measurement of vasomotor activity in these arteries. Vasomotor activity was measured, as 
previously published by our laboratory (39, 74). Briefly, immediately following extraction, 
cleaned CCAs were placed in 4oC Kreb’s Bicarbonate Buffer (concentration (mmol/L): 131.5 
NaCl, 5 KCl, 25 CaCl2, 1.2 NaH2PO4, 1.2 MgCl2, 0.025 EDTA, 13.5 NaHCO, 11.2 Glucose). 
Next, the arteries were cut into 2mm sections and mounted onto a force transducer that is part of 
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a wire myography unit. Once mounted, the arteries were placed in individual water-jacketed 
tissue baths each containing 5mL of 37oC Kreb’s Bicarbonate Buffer that were constantly 
aerated with 95% O2 and 5% CO2 (39, 74).  
The vessel segments were then equilibrated by washing with fresh buffer, followed by 
applying an optimal passive tension of 2.85g (as determined by Denniss and Rush, 2009); this 
process was performed a total of 3 times in 10 minute intervals. The segments were then tested 
for viability by maximally contracting the vessels with 10-4 M potassium chloride (KCl). This 
maximal contraction was left to plateau for 30 minutes before washing the vessels with fresh 
buffer in three 5-minute intervals. This 30-minute KCl contraction was then repeated for a 
second time before the segment went on to be used for measurements of vasomotor activity (e.g., 
endothelium-dependent vasorelaxation or endothelium-dependent vasocontraction), as described 
in detail below (39, 74). The maximum amplitude produced by each ring as the result of the 
second dose of KCl was utilized as each ring’s reference contraction.  
 
4.4.1 Endothelium-dependent vasorelaxation 
Following the equilibration period (described in 4.4), arteries were first pre-incubated for 
30 minutes in buffer containing either no drug (ND); L-name (10-4 M in bath) to inhibit NOS; 
indomethacin (10-5 M in bath) to non-selectively inhibit both COX-1 and COX-2; L-name and 
indomethacin to inhibit NOS and COX-1/-2; SC-560 (10-6 M in bath) to selectively inhibit COX-
1; or L-name and SC-560 to inhibit both NOS and COX-1. Next, all segments were 
precontracted with phenylephrine (PE; 10-6 M in bath). Once a plateau had been sustained for a 
minimum of 15 minutes, the endothelium-dependent vasorelaxation was measured in a dose-
dependent manner, in response to ACh (10-10 -10-4 M in bath) (39, 74). 
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Following the Ach dose-response measurements, the vessel segments were re-
equilibrated with 4 washes in 15-minute intervals. The same drug conditions, as used for the 
endothelium-dependent vasorelaxation measurements, were maintained during each of these 
washes. Following the final wash, all segments were again precontracted with PE (10-6 M in 
bath). Once a plateau had been sustained for a minimum of 15 minutes, vasorelaxation in 
response to the NO donor sodium nitroprusside (SNP; 10-12 – 10-4 M in bath) was measured in a 
dose-dependent manner to examine the sensitivity of the VSM to an external source of NO (i.e., 
independent of the production/bioavailability of NO by the endothelium). 
 
4.4.2 Endothelium-dependent vasocontraction 
Following the equilibration period (described in 4.4), arteries were first preincubated for 
30 minutes with L-name (10-4 M in bath) to inhibit NOS; L-name and indomethacin to inhibit 
both NOS and COX-1/-2; L-name and SC-560 to inhibit both NOS and COX-1; L-name and NS-
398 to inhibit both NOS and COX-2; or L-name and SQ29548 to inhibit both NOS and the TP 
receptor. Endothelium-dependent vasocontraction was then measured in a dose-dependent 
manner, in response to ACh (10-10 -10-4 M in bath) (39, 74).  
The buffer from these endothelium-dependent vasocontraction experiments was collected 
when the vessel segment reached its peak contraction (i.e., 1-2 minutes after the final dose of 
ACh was added to the tissue bath). These samples were flash frozen at -80oC for biochemical 
analyses that were performed at a later date (described in 4.5 Biochemical Analyses) (74). 
Following the ACh dose-response measurements, the vessel segments were re-
equilibrated with 4 washes in 15-minute intervals. The same drug conditions, as used for the 
endothelium-dependent vasocontraction measurements, were maintained during each of these 
washes. Following the final wash, vasocontraction in response to the TP receptor agonist 
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U46619 (10-9 – 10-5.5 M in bath) was measured in a dose-dependent manner to examine the 
sensitivity of the TP receptors to elicit vasocontraction. 
 
4.5 Biochemical Analyses 
 Once maximal ACh-stimulated vasocontraction had been achieved (i.e., 1-2 minutes after 
the final dose of ACh had been added) during the endothelium-dependent vasocontraction 
protocol, the buffer from these tissue baths was collected and frozen at -80oC. This tissue buffer 
was later used to measure PGI2 level by measuring its stable metabolite, 6-keto-prostaglandin 
F1!, as described by Cayman’s Chemical EIA Assay Kit, as we have done previously (74, 84). 
 
4.6 Data Analysis and Statistics 
 All data are expressed as the average ± standard error of the mean (SEM). Curve fitting 
and statistical comparisons were performed using GraphPad Prism. Ring cumulative tension 
responses to a vasomotor stimulus were individually best fit using a non-linear regression model 
to a sigmoidal dose-response curve. Maximum amplitude (MAX), dose resulting in 50% of 
MAX (EC50), and area under the curve (AUC) were generated then averaged within their 
respective group. One-way or two-way ANOVA with Tukey post-hoc tests, when necessary, 
were used for multiple within and/or between group comparisons. Independent groups were 
compared using two-tailed, unpaired Student’s t-tests. Statistical significance was considered if 
p<0.05. 
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5.0 Results 
5.1 Physical Characteristics of Animal Models 
 Table 1 presents the data describing the physical characteristics of the animals used for 
this study. All animals gained weight over the 6-week treatment period. The final body weights 
of WKY were ~5-10% greater than SHR (Table 1). Furthermore, two-way ANOVA analyses 
demonstrate both a strain and stress effect on weight gain, wherein WKY gained more weight 
compared to SHR and UCMS animals gained more weight compared to control animals 
throughout the 6-week protocol (Table 1). Food and water monitoring throughout the treatment 
period determined that SHR consumed ~10-25% more food and ~15-25% more water than WKY 
(Table 1), a finding that has been previously documented (84, 85). However, it is unknown 
whether these increases are a result of increased consumption by SHR or increased spillage (84, 
85). Stress had no significant effect on food and/or water consumption in WKY (Table 1). Stress 
had no significant effect on water consumption in SHR, however SHR in the UCMS group 
consumed ~10% more food than SHR in the control group (Table 1).  
Measuring the left ventricle to body weight ratio (LV:BW) is a commonly used surrogate 
in place of measuring blood pressure to determine the presence of hypertension in an animal. The 
left ventricle to body weight ratio is significantly greater in animals with hypertension due to 
systemic pressure-induced left ventricular hypertrophy (LVH), compared to normotensive 
animals (39). As has been observed previously in our lab (39), the left ventricle to body weight 
ratio was significantly greater (~15-30%) in SHR compared to WKY (Table 1), demonstrating 
the presence of hypertension in the SHR animals used in this study. No significant stress effect 
on left ventricle to body weight ratio was observed in either strain (Table 1). 
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5.2 Behavioural Characteristics of Animal Models 
5.2.1 Splash Test 
 Using the Fisher’s Exact Test it was determined that significantly fewer WKY groomed 
at all during the splash test, compared to SHR (p=0.005). Of all of the animals that underwent 
the splash test, 13 of the 24 WKY and 3 of the 24 SHR did not groom at all when sprayed with 
the 10% sucrose solution (Figure 3A). Of the 13 WKY that did not groom, 7 were from the 
control group and 6 were from the UCMS group. Of the 3 SHR that did not groom, 1 was from 
the control group and 2 were from the UCMS group.  
Of those that did groom, the latency of grooming was greatest in the SHR UCMS group 
and, unexpectedly, was lowest in the WKY UCMS group (Figure 3B). No significant stress 
effect on latency of grooming was seen in SHR (p=0.3024), however, there was a significant 
stress effect in WKY (p=0.0036). No significant strain effect was seen between the control 
groups (p=0.9221), however, grooming latency was significantly greater in SHR UCMS 
compared to WKY UCMS (p=0.0082).  
Additionally, there was a significant strain effect (p<0.0001) on grooming frequency, 
wherein WKY groomed significantly less frequently in both the Control and UCMS groups, 
compared to SHR (Figure 3C). A significant stress effect was present in the SHR animals 
(p=0.0050), wherein SHR in the UCMS group groomed significantly less frequently than SHR in 
the control group. Unexpectedly, stress had no significant effect on grooming frequency in WKY 
(p=0.5581).  
 
5.2.2 Coat Status 
The intraclass correlation coefficient to assess the inter-rater reliability (i.e., the degree of 
agreement among the two raters) ranged between 0.69-1.0 across the eight different body 
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regions. The neck had the lowest degree of agreement (0.69) and the forelimb had the greatest 
degree of agreement (1.0). 
Coat status significantly increased (i.e., coats became significantly dirtier) over time 
(p<0.0001) in both WKY and SHR (Figure 3D). A significant strain effect was also present 
wherein the coats of the WKY were significantly dirtier than those of the SHR in both the 
control (p=0.0009) and the UCMS groups (p=0.0062) (Figure 3D).  
A significant difference in the coat status between UCMS and control groups was also 
detected in both WKY (p<0.0001) and SHR (p=0.0006), wherein the coats of animals in the 
UCMS groups were significantly dirtier than those in the control groups. Coats were found to be 
significantly dirtier after only one week of UCMS in SHR (p=0.0027) and remained significantly 
dirtier for each week that followed. Likewise coats were found to be significantly “dirtier” after 
only one week of UCMS in WKY (p=0.0114), however, this significant difference was not 
observed at weeks 4 (p=0.0620), or 5 (p=0.0548) (Figure 3D). 
 
5.3 Vascular Myography Data 
5.3.1 Absolute and Relative KCl and PE Contractile Activity  
 KCl-stimulated contractions were greater in UCMS compared to their respective control 
group in WKY (p<0.0001; Figure 4A) and SHR (p<0.0001; Figure 4A). Likewise, KCl-
stimulated contractions were greater in SHR compared to WKY in the control (p<0.0001; Figure 
4A) and UCMS (p<0.0001; Figure 4A) groups. Contractile responses to the first dose of PE (10-
6M) were ~25% lower in SHR compared to WKY (Figure 4B) across all drug conditions, as has 
been observed previously in our lab (39, 86). No significant differences in developed tension in 
response to the first dose of PE (PE1; 10-6M) were found between Control and UCMS groups in 
WKY (p=0.9027; Figure 4B) or SHR (p=0.0668 Figure 4B). Similar results were obtained when 
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developed tension in response to PE1 (10-6M) was analyzed relative to each ring’s maximal 
contraction to KCl (Figure 4C). No significant differences in developed tension to the second 
dose of PE (PE2; 10-6M) were found between strains (p=0.6117) or between control and UCMS 
groups (p=9135) (Figure 4D).  
Previous research in our lab (39) has observed that the ratio of developed tension in 
response to PE (10-6M) in drug conditions containing L-name compared to those that do not 
contain L-name are greater in WKY compared to SHR. These data suggest that L-name has a 
greater effect in CCA from WKY compared to SHR. This is most likely due to production and/or 
bioavailability of NO already being lower in SHR (39, 87).  Similar results were also observed in 
the current study. In SHR CON (Figure 5A) and SHR UCMS (Figure 5B), the developed tension 
in response to PE1 (10-6M) was ~15% greater in the L-name, L-name+Indo, and L-name+SC-
560 drug conditions compared to the ND, Indo, and SC-560 drug conditions, respectively. 
However, the developed tension is response to PE1 (10-6M) was ~30% greater in the L-name, L-
name+Indo, and L-name+SC-560 drug conditions compared to ND, Indo, and SC-560 drug 
conditions, respectively, in WKY CON (Figure 5C) and WKY UCMS (Figure 5D). 
 
5.3.2 Agonist-stimulated Vasocontractile Responses 
 Three different figure formats are provided to demonstrate differences between strains 
(Fig. 6-7), drug conditions (Fig. 8, 11), and stress and control groups (Fig. 9-10).  
 
5.3.2.1 ACh-stimulated vasocontraction is attenuated in quiescent SHR and WKY CCA that 
underwent UCMS compared to their respective control groups  
 As has been shown previously in our lab (39), ACh-stimulated vasocontraction in 
quiescent CCA preincubated with L-name was augmented in SHR compared to WKY (Table 2). 
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This result was consistent across the control (Table 2; Figure 6A) and UCMS (Table 2; Figure 
7A) groups.  
The effects of COX- and TP receptor-inhibitors were investigated in the presence of L-
name to optimize the ACh-stimulated contractions (39, 29, 88, 89). Non-selectively inhibiting 
COX through preincubation with indomethacin impeded endothelium-dependent vasocontraction 
in all four groups (i.e., WKY control and UCMS and SHR control and UCMS) (Table 2; Figure 
8). Similarly, blocking the TP receptor through preincubation with SQ29548 also impeded the 
contractile response to ACh in all four groups (Table 2; Figure 8). Furthermore, selective 
inhibition of COX-1 or COX-2 through preincubation with SC-560 or NS-398, respectively, also 
blunted endothelium-dependent vasocontraction in all four groups (Table 2; Figure 8).  
 Unexpectedly, UCMS attenuated endothelium-dependent vasocontraction in response to 
increasing doses of ACh, in both WKY (Table 2; Figure 9A) and SHR (Table 2; Figure 10A). 
Furthermore, this attenuation was greater in WKY (~55%) compared to SHR (~40%).  
 
5.3.2.2 U46619-stimulated vasocontraction elicited similar vasocontractile responses across all 
groups 
 Increasing doses of U46619 elicited similar sigmoidal dose-response curves in the 
presence of L-name, the COX-1 inhibitor SC-560, the COX-2 inhibitor NS-398, and the non-
selective COX-inhibitor indomethacin, across all four groups (Table 3; Figure 11).  
 In all four groups the lower doses of U46619 (10-9 – 10-6.5M) were insufficient to elicit 
any vasocontraction in the presence of the TP-receptor antagonist, SQ29548. Higher 
concentrations of U46619 (10-6 and 10-5.5M), however, elicited similar vasocontractile responses 
in all four groups (Table 3; Figure 11).   
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5.3.3 Agonist-stimulated Vasodilatory Responses 
 Three different figure formats are provided to demonstrate differences between drug 
conditions (Fig. 12,17), strains (Fig. 13-14), and stress and control groups (Fig. 15-16). 
 
5.3.3.1 ACh-stimulated, endothelium-dependent vasorelaxation is augmented in precontracted 
SHR and WKY CCA that underwent UCMS compared to their respective control groups 
 CCA precontracted with PE (10-6M) from both WKY and SHR exhibited ACh-
stimulated, endothelium-dependent vasorelaxation in both the control and UCMS groups (Table 
4; Figure 12). Preincubation with L-name to inhibit NOS impeded this vasorelaxation in all four 
groups (Figure 12), suggesting that this ACh-stimulated vasodilatory response is NOS-mediated. 
Additionally, when CCA was preincubated with L-name in addition to the COX-inhibitors, 
indomethacin and SC-560, endothelium-dependent vasodilatory responses to ACh were also 
impeded, due to the blocking of the NOS-system (Figure 12).  
Non-selective COX-inhibition, with indomethacin, slightly augmented endothelium-
dependent vasodilatory responses to ACh in SHR control (Table 4; Figure 12B) and UCMS 
(Table 4; Figure 12D) groups compared to the ND condition. Non-selective COX-inhibition, 
with indomethacin, also augmented the endothelium-dependent vasodilatory response in the 
WKY control group compared to the no drug condition (Table 4; Figure 12A), but had no effect 
in the WKY UCMS group (Table 4; Figure 12C). 
 As has been previously demonstrated in our lab (39, 74), SHR exhibited attenuated ACh-
stimulated, endothelium-dependent vasorelaxation compared to WKY in both control (Table 4; 
Figure 13A) and UCMS (Table 4; Figure 14A) groups.  
! LJ!
 Unexpectedly, UCMS augmented endothelium-dependent vasorelaxation in response to 
increasing doses of ACh, in both WKY (Table 4; Figure 15A) and SHR (Table 4; Figure 16A). 
Furthermore, this augmentation was slightly greater in WKY (~10%) compared to SHR (~7%). 
 
5.3.3.2 SNP-stimulated vasorelaxation elicited similar vasodilatory responses across all groups 
 Increasing doses of SNP elicited similar sigmoidal dose-response curves across all drug 
conditions in all four groups, wherein no significant differences were seen between strains or 
between the UCMS and Control groups (Table 5; Figure 17). Furthermore, no significant 
differences were seen between drug conditions, within each of the four groups (Table 5; Figure 
17).  
 
5.4 Biochemical PGI2 Assessment 
 PGI2 levels were measured through measuring levels of the PGI2 stable metabolite, 6-
keto PGF1!, in the buffer collected from the tissue baths following Ach dose-response curves 
(i.e., the same rings as displayed in Figure 8). As has been observed previously in our lab (84), 
PGI2 levels were significantly greater in SHR compared to WKY in the LN condition (p=0.0087; 
Figure 18A). However, no significant differences in PGI2 levels were seen between WKY and 
SHR in the LN+Indo (p=0.1144; Figure 18B) or LN+SQ29548 (p=0.5462; Figure 18C) drug 
conditions. Furthermore, COX-inhibition with indomethacin reduced PGI2 levels compared to 
the L-name condition, as has been demonstrated previously in our lab (84). This decrease 
reached significance in the WKY CON (p=0.0440; Figure 19A), SHR CON (p=0.0124; Figure 
19B), and SHR UCMS (p=0.0074; Figure 19B) groups, but not in the WKY UCMS group 
(p=0.0520; Figure 19A). Stress had no significant effect on PGI2 levels in WKY or SHR (Figure 
18). 
! LK!
Table 1: Physical Characteristics of WKY and SHR in Control and UCMS groups!
 
 
WKY  SHR  p value 
 CON UCMS  CON UCMS  
Stress 
Effect 
Strain 
Effect 
Stress 
x 
Strain 
   Age (weeks) 34.2±0.59 33.9±0.26  33.5±0.72 32.8±0.17  0.3090 0.0717 0.7673 
Initial body weight (g) 380±4.0 377±4.6  350±8.4b 365±8.6  0.3711 0.0034 0.1842 
Final body weight (g) 413±6.5 415±5.2  365±9.2b 390±9.1  0.0938 <0.0001 0.1307 
Change in body weight (g) 33.9±4.3 38.2±3.1  15.7±1.9b 25.6±2.2b  0.0221 <0.0001 0.3578 
   Food consumption (g/day) 18.6±0.38 18.1±0.27  20.2±0.43b 22.2±0.25a,b  0.0378 <0.0001 0.0010 
Water consumption (mL/day) 36.1±0.69 35.2±1.01  42.3±1.77b 43.0±1.76b  0.8769 <0.0001 0.6095 
Left ventricle (mg) : 
     body weight (g) 
2.12±0.08 2.22±0.14  2.78±0.07b 2.65±0.07b  0.8763 <0.0001 0.2421 
Data are represented as the average mean ! SEM. P<0.05 was considered statistically significant. From post-hoc 
analyses: a p<0.05 vs. CON within WKY or SHR; b p<0.05 vs. WKY within corresponding CON or UCMS group.  
 
 
 
!! ""!
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Figure 3: Behavioural tests (splash test and coat status) used to examine the efficacy of the UCMS protocol. Grooming Rate (A), Latency (B) and 
frequency (C) of facial grooming following a 10% sucrose solution spray. Grooming rate was analyzed using the Fisher’s Exact Test and any difference where 
p<0.05 was considered statistically significant. Data for grooming latency and frequency are represented as the average mean ! SEM. p<0.05 was considered 
statistically significant. From post-hoc analyses: * p<0.05 vs. CON within WKY or SHR; ! p<0.05 vs. WKY within corresponding CON or UCMS group. (D) 
Cumulative weekly coat status score represented as the average mean ! SEM; analyzed using 2-way ANOVA where p<0.05 was considered statistically 
significant. 
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FIGURE 4: Absolute developed tension in response to 4M KCl, and developed tension to PE (10-6M) in both absolute terms and relative to KCl 
contractions. Viability of arterial rings was assessed through contractile response to 4M KCl (A). Then, rings used to investigate endothelium-dependent 
vasorelaxation were precontracted with a first dose of PE (PE1; 10-6M); this data is represented in both absolute terms (B), and relative to the KCl contractions 
(C). These same rings were precontracted a second time, following the Ach dose-response curves, with a second dose of PE (PE2; 10-6M) (D) before 
investigating VSM sensitivity with increasing doses of SNP. Data are represented as the average mean ! SEM. p<0.05 was considered statistically significant. 
From post-hoc analyses: * p<0.05 vs. CON within WKY or SHR; ! p<0.05 vs. WKY within corresponding CON or UCMS group. 
!! "$!
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Figure 5: The ratio of developed tension in response to PE1 in drug conditions with L-name compared to drug conditions without L-name. The relative 
developed tension in reponse to the first dose of PE (PE1; 10-6M) in the LN, LN+Indo, and LN+SC-560 drug conditions relative to the ND, Indo, and SC-560 
drug conditions, respectively. Data are represented as the average mean ! SEM. p<0.05 was considered statistically significant. 
!! "%!
Table 2: Ach-stimulated vasocontractile curve-fit parameter analyses 
 
 
WKY  SHR  p value 
 CON UCMS  CON UCMS  
Stress 
Effect 
Strain 
Effect 
Stress 
x 
Strain 
LN (L-name)          
EC50 (uM) 2.58±0.79 2.48±1.20  2.44±0.70 1.62±0.43  0.5568 0.4011 0.5309 
MAX (%) 27.25±5.95 11.86±2.91a  48.5±9.0 33.40±6.51  0.0337 0.0037 0.9854 
AUC 54.22±10.98 24.87±5.43a  84.3±15.4 65.42±12.76  0.0560 0.0081 0.7046 
LN+Indo          
EC50 (nM) --- ---  --- ---  --- --- --- 
MAX (%) 0.05±0.95 0.85±0.32  1.58±1.12 -0.58±0.88  0.4508 0.9144 0.0996 
AUC 2.83±1.48 4.21±0.85  7.42±1.47 5.02±1.18  0.6924 0.0498 0.1560 
LN+SC-560          
EC50 (uM) --- ---  --- ---  --- --- --- 
MAX (%) 0.92±0.90 1.06±0.59  2.69±0.59 1.28±0.81  0.3860 0.1767 0.2932 
AUC 9.82±1.91 8.26±1.39  8.33±1.15 7.14±1.03  0.3310 0.3552 0.8935 
LN+NS-398          
EC50 (nM) --- ---
  --- ---  --- --- --- 
MAX (%) 3.07±1.33 1.12±0.94  -0.48±1.49 2.40±1.45  0.7184 0.3817 0.0723 
AUC 11.96±4.40 10.35±2.53  9.42±1.45 6.13±1.20  0.3752 0.2257 0.7588 
LN+SQ-29,548          
EC50 (nM) --- ---
  --- ---  --- --- --- 
MAX (%) 1.65±0.91 1.45±0.81  5.51±1.16 3.15±1.41  0.2355 0.0124 0.3127 
AUC 9.62±2.06 8.67±2.15  14.48±2.65 9.56±1.60  0.1846 0.1934 0.3671 
 
Curve-fit parameter analyses corresponding to data depicted in Figure 8. EC50, dose resulting in 50% of maximum curve amplitude; MAX, maximum curve 
amplitude; AUC, area under the curve. From post-hoc analysis: a p<0.05 vs. CON within WKY or SHR; b p<0.05 vs. WKY from corresponding CON or UCMS 
condition. Data represented as the average ! SEM and are expressed relative to a maximal 60 mM KCl dose. 
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Figure 6: ACh-stimulated vasocontraction in quiescent CCA of Control animals, comparing WKY versus 
SHR. Arterial rings were preincubated with L-name, L-name+Indo, L-name+SC-560, L-name+SQ29548, or L-
name+NS-398 before exposure to cumulative doses of ACh. Data represents average ! SEM and are expressed 
relative to each ring’s maximal contraction to KCl; p<0.05 was considered statistically significant. !
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Figure 7: ACh-stimulated vasocontraction in quiescent CCA of UCMS animals, comparing WKY versus 
SHR. Arterial rings were preincubated with L-name, L-name+Indo, L-name+SC-560, L-name+SQ29548, or L-
name+NS-398 before exposure to cumulative doses of ACh. Data represents average ! SEM and are expressed 
relative to each ring’s maximal contraction to KCl; p<0.05 was considered statistically significant.
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Figure 8: ACh-stimulated vasocontraction in quiescent CCA of Control (top) and UCMS (bottom) animals across various drug conditions. Arterial rings 
were preincubated with L-name, L-name+Indo, L-name+SC-560, L-name+SQ29548, or L-name+NS-398 before exposure to cumulative doses of ACh. Data 
represents average !  SEM and are expressed relative to each ring’s maximal contraction to KCl; p<0.05 was considered statistically significant.
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Figure 9: ACh-stimulated vasocontraction in quiescent CCA of WKY animals, comparing CON versus 
UCMS. Arterial rings were preincubated with L-name, L-name+Indo, L-name+SC-560, L-name+SQ29548, or L-
name+NS-398 before exposure to cumulative doses of ACh. Data represents average ! SEM and are expressed 
relative to each ring’s maximal contraction to KCl; p<0.05 was considered statistically significant. !
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Figure 10: ACh-stimulated vasocontraction in quiescent CCA of SHR animals, comparing CON versus 
UCMS. Arterial rings were preincubated with L-name, L-name+Indo, L-name+SC-560, L-name+SQ29548, or L-
name+NS-398 before exposure to cumulative doses of ACh. Data represents average ! SEM and are expressed 
relative to each ring’s maximal contraction to KCl; p<0.05 was considered statistically significant.
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Table 3: U46619-stimulated vasocontractile curve-fit parameter analyses. 
 WKY  SHR  p value 
 CON UCMS  CON UCMS  
Stress 
Effect 
Strain 
Effect 
Stress 
x 
Strain 
LN (L-name)          
EC50 (uM) 12.86±1.46 11.48±1.19  17.74±1.98 14.65±3.11  0.2918 0.0616 0.6847 
MAX (%) 158.7±6.45 155.4±10.44  146.1±3.75 132.6±4.50  0.2281 0.0128 0.4610 
AUC 352.7±13.25 338.7±21.64  311.9±10.86 291.6±11.27  0.2593 0.0054 0.8360 
LN+Indo          
EC50 (nM) 32.57±9.09 17.13±3.40  26.35±2.46 23.62±3.06  0.0714 0.9780 0.1979 
MAX (%) 144.8±16.29 144.0±4.77  147.1±4.06 126.6±5.11  0.2091 0.3674 0.2406 
AUC 274.9±16.53 310.8±13.82  295.3±8.32 257.4±10.51b  0.9330 0.1984 0.0076 
LN+SC-560          
EC50 (uM) 18.61±1.04 13.18±0.85a  21.15±1.74 14.01±0.98a  <0.001 0.1369 0.4431 
MAX (%) 163.1±9.34 146.2±5.19  154.7±2.71 135.8±4.93  0.0075 0.1477 0.8752 
AUC 341.0±19.26 321.7±10.81  321.4±7.05 295.9±8.23  0.0884 0.0836 0.8089 
LN+NS-398          
EC50 (nM) 15.59±1.80 17.01±5.06  20.13±3.31 9.07±1.08  0.1367 0.5897 0.0590 
MAX (%) 162.4±7.75 159.2±6.17  137.1±5.11b 139.5±4.61  0.9487 0.0012 0.6374 
AUC 350.9±11.45 328.5±10.38  282.5±18.18b 309.2±14.59  0.8861 0.0078 0.1106 
LN+SQ-29,548          
EC50 (nM) 1.73±0.27 1.50±0.10  1.97±0.27 1.49±0.14  0.0876 0.5758 0.5353 
MAX (%) 140.2±22.28 117.5±7.90  98.40±9.71 92.49±8.07  0.2974 0.0178 0.5396 
AUC 53.52±5.99 56.86±4.24  37.80±2.87 42.18±4.23  0.3994 0.0017 0.9082 
 
Curve-fit parameter analyses corresponding to data depicted in Figure 11. EC50, dose resulting in 50% of maximum curve amplitude; MAX, maximum curve 
amplitude; AUC, area under the curve. From post-hoc analysis: a p<0.05 vs. CON within WKY or SHR; b p<0.05 vs. WKY from corresponding CON or UCMS 
condition. Data represented as the average ! SEM and are expressed relative to a maximal 60 mM KCl dose. 
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Figure 11: U46619-stimulated vasocontraction in quiescent CCA of Control (top) and UCMS (bottom) animals across various drug conditions. Arterial 
rings were preincubated with L-name, L-name+Indo, L-name+SC-560, L-name+SQ29548, or L-name+NS-398 before exposure to cumulative doses of U46619. 
Data represents average ! SEM and are expressed relative to each ring’s maximal contraction to KCl; p<0.05 was considered statistically significant. 
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Table 4: ACh-stimulated vasodilatory curve-fit parameter analyses
 
Curve-fit parameter analyses corresponding to data depicted in Figure 12. EC50, dose resulting in 50% of maximum curve amplitude; MAX, maximum curve 
amplitude; AUC, area under the curve. From post-hoc analysis: a p<0.05 vs. CON within WKY or SHR; b p<0.05 vs. WKY from corresponding CON or UCMS 
condition. Data represented as the average ! SEM and are expressed relative to a maximal dose of PE (10-6M). 
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Figure 12: ACh-stimulated vasorelaxation in precontracted (PE 10-6M) CCA of Control (top) and UCMS (bottom) animals across various drug 
conditions. Arterial rings were preincubated with ND, L-name, Indo, L-name+Indo, SC-560, or L-name+SC-560 before exposure to cumulative doses of ACh. 
Data represents average ! SEM and are expressed relative to each ring’s maximal contraction to PE (10-6M); p<0.05 was considered statistically significant.
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Figure 13: ACh-stimulated vasorelaxation in precontracted (PE 10-6M) CCA of Control animals, comparing 
WKY versus SHR. Arterial rings were preincubated with ND, L-name, Indo, L-name+Indo, SC-560, or L-
name+SC-560 before exposure to cumulative doses of ACh. Data represents average ! SEM and are expressed 
relative to each ring’s maximal contraction to PE (10-6M); p<0.05 was considered statistically significant.     
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Figure 14: ACh-stimulated vasorelaxation in precontracted (PE 10-6M) CCA of UCMS animals, comparing 
WKY versus SHR. Arterial rings were preincubated with ND, L-name, Indo, L-name+Indo, SC-560, or L-
name+SC-560 before exposure to cumulative doses of ACh. Data represents average ! SEM and are expressed 
relative to each ring’s maximal contraction to PE (10-6M); p<0.05 was considered statistically significant. 
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Figure 15: ACh-stimulated vasorelaxation in precontracted (PE 10-6M) CCA of WKY animals, comparing 
CON versus UCMS. Arterial rings were preincubated with ND, L-name, Indo, L-name+Indo, SC-560, or L-
name+SC-560 before exposure to cumulative doses of ACh. Data represents average ! SEM and are expressed 
relative to each ring’s maximal contraction to PE (10-6M); p<0.05 was considered statistically significant. 
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Figure 16: ACh-stimulated vasorelaxation in precontracted (PE 10-6M) CCA of SHR animals, comparing 
CON versus UCMS. Arterial rings were preincubated with ND, L-name, Indo, L-name+Indo, SC-560, or L-
name+SC-560 before exposure to cumulative doses of ACh. Data represents average ! SEM and are expressed 
relative to each ring’s maximal contraction to PE (10-6M); p<0.05 was considered statistically significant.
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Table 5: SNP-stimulated vasodilatory curve-fit parameter analyses   
 
 
Curve-fit parameter analyses corresponding to data depicted in Figure 17. EC50, dose resulting in 50% of maximum curve amplitude; MAX, maximum curve 
amplitude; AUC, area under the curve. From post-hoc analysis: a p<0.05 vs. CON within WKY or SHR; b p<0.05 vs. WKY from corresponding CON or UCMS 
condition. Data represented as the average ! SEM and are expressed relative to a maximal dose of PE (10-6M).!
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Figure 17: SNP-stimulated vasorelaxation in precontracted (PE 10-6M) CCA of Control (top) and UCMS (bottom) animals across various drug 
conditions. Arterial rings were preincubated with ND, L-name, Indo, L-name+Indo, SC-560, or L-name+SC-560 before exposure to cumulative doses of SNP. 
Data represents average ! SEM and are expressed relative to each ring’s maximal contraction to PE (10-6M); p<0.05 was considered statistically significant.
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Figure 18: PGI2 levels in the tissue buffer surrounding CCA segments from WKY and SHR comparing the 
Control and UCMS groups. The concentration of the stable PGI2 metabolite, 6-keto prostaglandin F1! (PGF1!), 
in the tissue buffer surrounding CCA segments from WKY and SHR in the Control versus UCMS groups incubated 
with LN (A), LN+Indo (B), or LN+SQ29548 (C) following the maximal dose of ACh (10-4M) in the vasocontractile 
dose-response curves (Figure 8). Data are represented as the average ! SEM. p<0.05 was considered statistically 
significant. From post-hoc analyses: ! p<0.05 vs. WKY within corresponding CON or UCMS group.  
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Figure 19: PGI2 levels in the tissue buffer surrounding CCA segments from WKY and SHR comparing across drug conditions. The concentration of the 
stable PGI2 metabolite, 6-keto prostaglandin F1! (PGF1!), in the tissue buffer surrounding CCA segments from WKY (A) and SHR (B), comparing the Control 
and UCMS groups, and from Control (C) and UCMS (D), comparing WKY and SHR, following the maximal dose of ACh (10-4M) in the vasocontractile dose-
response curves (Figure 8). Data are represented as the average ! SEM. p<0.05 was considered statistically significant. From post-hoc analyses: * p<0.05 vs. 
LN+Indo within corresponding strain or stress group. !
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6.0 Discussion 
Chronic mental stress has been shown to be associated with several CVD risk factors and 
has therefore been emerging as an independent risk factor for CVD (45, 46, 52, 53, 54, 90, 91, 
92). However, a significant amount of investigation remains to identify how chronic mental 
stress can lead to CVD, on a mechanistic level (56). This thesis aimed to investigate the effects 
of UCMS on endothelial function in WKY and SHR rats. While some of the hypotheses were 
accepted, others were rejected. Overall, the main findings from this project were:  
 
1. Splash test and coat status results suggest that the UCMS protocol was sufficient to 
induce mental stress. 
2. Animal strain, but not stress, significantly affected left ventricle to body weight ratio. 
3. Compared to their respective controls, UCMS augmented endothelium-dependent 
vasorelaxation. 
4. Compared to their respective controls, UCMS attenuated endothelium-dependent 
vasocontraction. 
5. UCMS-induced augmentation of endothelium-dependent vasorelaxation and attenuation 
of endothelium-dependent vasocontraction were not due an effect of UCMS on VSM 
sensitivity, an increase in NO bioavailability, or a reduction in PGI2 levels 
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6.0.1 Splash test and coat status results suggest that the UCMS protocol was sufficient to 
induce mental stress 
Behavioural analyses, such as monitoring coat status and performing splash tests (as 
described in 4.3 Efficacy Measures of UCMS Protocol), often accompany the physiological and 
biochemical analyses when using a psychological intervention/protocol, such as the UCMS 
protocol (65, 66, 67, 70, 71). This is of importance because the physiological and biochemical 
data are not relevant if the intervention did achieve the desired outcome. Performing behavioural 
analyses, such as the splash test and coat status, to ensure that the UCMS was inducing stress in 
the UCMS animals was particularly important in the current study, since it is the first time that 
the UCMS protocol has been used in our lab. 
The splash test and coat status data from the SHR animals in our study is comparable to 
what has been found in previous studies (65, 67, 70) and suggests that the UCMS protocol was 
sufficient to induce depressive symptoms in the animals in the SHR UCMS group compared to 
the SHR control group. However, the splash test data and coat status data in WKY was not 
consistent with previous literature (65, 67, 70). Grooming frequency during the splash test was 
significantly lower (i.e., to a similar degree as SHR UCMS animals) in both the WKY UCMS 
group and the WKY control group. Additionally, the coat status scores of WKY were only 
significantly greater (i.e., dirtier) in the UCMS group compared to the control group at weeks 1 
and 2. Moreover, the coat status scores were higher (i.e., dirtier) in WKY compared to SHR, in 
both the CON and UCMS groups.  
With this study being the first to investigate the effects of the UCMS protocol in WKY 
and SHR rats it is possible that these unexpected results may be due the strain differences in the 
animals we used compared to animals used in previous studies. For instance, WKY rats are 
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classified as an animal model of depression (93, 94, 95), therefore substantiating the possibility 
that the strain of rat chosen for this study could have contributed to these results. Our splash test 
and coat status data build on the already existing literature that have demonstrated that WKY are 
significantly more depressed than several other rat strains (e.g., SHR, Wistar, Sprague-Dawley, 
etc.) (93, 94, 95). This was determined by the various behaviours exhibited by each of these rat 
strains in a series of behavioural tests. For example, social avoidance was demonstrated by WKY 
in the social interactions test (93). Learned helplessness has also been demonstrated in WKY, as 
determined by the WKY’s lack of motivation to escape the forced swim test (93) and the 
shuttlebox escape test (93). Moreover, these investigators established that these behaviours were 
not present in Wistar, Sprague-Dawley, Fisher-344, or SHR rats, further demonstrating the 
increased presence of depressive behaviours in WKY compared to other rat strains (93). 
Additionally, while no significant strain effect in the latency of grooming was detected 
during the splash test, statistical analysis could only be performed for the animals that groomed 
at all. Since significantly fewer WKY (13 of 24) groomed at all during the splash test compared 
to SHR (21 of 24), together with the fact that a reduction in grooming is considered a sign of 
depressive behaviour, this data would further suggest that WKY rats are an animal model of 
depression.   
 Overall, the lack of grooming by WKY during the splash test, and the dirtier coats in 
WKY compared to SHR further demonstrates the presence of depression in the WKY rat strain 
and should be considered when choosing the animal model for any experiment involving a 
behavioural component.   
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6.0.2 Animal strain, but not stress, significantly affected left ventricle to body weight ratio 
An increase in left ventricle to body weight ratio is present in animals with hypertension 
as a result of the systemic pressure-induced left ventricular hypertrophy (LVH) (39, 96, 97). The 
left ventricle to body weight ratio was significantly greater in SHR compared to WKY in both 
the control and UCMS groups, suggesting the presence of LVH in these animals. These results 
were expected and have been observed previously in our lab (39) and by others (96, 97, 98, 99). 
However, since chronic mental stress has been shown to be associated with several CVD risk 
factors, including hypertension (90, 91, 92), it may have been hypothesized that the UCMS 
would have caused LVH in WKY and exaggerated the already existing LVH in SHR. However, 
while LVH can develop over the course of only a few weeks, it usually takes months to develop 
(98). It is therefore likely like that the 6-week UCMS protocol was not long enough for the 
structural changes associated with LVH to occur. A study published by Puzserova et al. 
demonstrated that 8 and 12 weeks of chronic stress, induced by crowded housing, was 
insufficient to induce left ventricular hypertrophy in WKY (58), further suggesting that a longer 
protocol may need to be used for LVH to develop. 
 
6.0.3 Compared to their respective controls, UCMS augmented endothelium-dependent 
vasorelaxation  
As expected, endothelium-dependent, ACh-stimulated vasorelaxation in precontracted 
CCA was attenuated in SHR compared to WKY. Additionally, inhibiting NOS with L-name 
inhibited endothelium-dependent vasorelaxation, suggesting that endothelium-dependent 
vasorelaxation in WKY and SHR is NO-mediated. Furthermore, non-selectively inhibiting COX 
with indomethacin reversed the impairment in endothelium-dependent vasorelaxation in both 
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SHR groups, suggesting that this impairment is, at least in part, due to over-active EDCF 
activity. These results were expected, as they have been observed previously in our lab (39, 74) 
and by others in aorta of WKY and SHR (75, 76). 
Unexpectedly, UCMS augmented endothelium-dependent vasorelaxation in both WKY 
and SHR. However, previous studies that have investigated the effects of the UCMS protocol on 
endothelial function have done so using mostly mice and Wistar rats (65, 66, 68, 69). The current 
study is the first to examine the effects of the UCMS protocol on endothelial function in WKY 
and SHR CCA. A previous study by Puzserova et al. investigated endothelium-dependent, ACh-
stimulated vasorelaxation in femoral arteries from WKY following 8 or 12 weeks of chronic 
stress, induced by crowded housing (i.e., 5 rats/cage instead of 4 rats/cage) (58). Eight weeks of 
crowded housing resulted in augmented endothelium-dependent vasorelaxation compared to the 
control group, similar to what was observed in the current study. Interestingly, 12 weeks of 
crowded housing resulted in attenuated endothelium-dependent vasorelaxation compared to the 
control group (58). It is, therefore, possible that the duration of the UCMS protocol used in the 
current study was not sufficiently long enough to induce endothelial dysfunction. If the protocol 
had been longer in duration, the UCMS may have led to attenuated vasorelaxation and/or 
augmented vasocontraction, as originally hypothesized, and as observed in the Puzserova et al. 
study. 
  
6.0.4 Compared to their respective controls, UCMS attenuated endothelium-dependent 
vasocontraction 
Endothelium-dependent, ACh-stimulated vasocontraction in quiescent CCA was 
augmented in SHR compared to WKY, due to overactive EDCF activity, as has been 
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demonstrated previously in our lab (39, 74) and by others in aorta of WKY and SHR (31, 75). 
Non-selectively inhibiting COX with indomethacin blocked endothelium-dependent 
vasocontraction in WKY and SHR, in both the control and UCMS groups. Moreover, blocking 
the TP receptor with the TP receptor-agonist SQ-29548 also blocked endothelium-dependent 
vasocontraction. These results are consistent with previous work in our lab (39, 74), and 
demonstrate that the endothelium-dependent vasocontraction in the WKY and SHR, in both the 
control and UCMS groups, is both COX- and TP receptor-mediated.  
   Unexpectedly, however, UCMS attenuated endothelium-dependent vasocontraction in 
both WKY and SHR. To date, no studies have specifically investigated the effects of UCMS on 
endothelium-dependent vasocontraction. However, Fuchs et al. (59) demonstrated that chronic 
behavioural stress, induced by air-jets blowing compressed air on the animals, impaired 
endothelium-dependent vasorelaxation in old (18 mo.) BHR, and suggested that this impairment 
may have been due overactive EDCF activity (see 1.6.2 Chronic Mental Stress and Augmented 
Endothelium-Dependent Vasocontraction). However, this same study demonstrated that the 
chronic behavioural stress enhanced endothelium-dependent vasorelaxation in young (3 mo.) 
BHR (59). It is therefore possible that the age of the animals in the current study (i.e., ~ 8 mo.) 
could have contributed to the unexpected UCMS-induced attenuation of endothelium-dependent 
vasocontraction and/or augmentation of endothelium-dependent vasorelaxation.   
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6.0.5 UCMS-induced augmentation of endothelium-dependent vasorelaxation and 
attenuation of endothelium-dependent vasocontraction were not due an effect of UCMS on 
VSM sensitivity, an increase in NO bioavailability, or a reduction in PGI2 levels 
Impairment in endothelium-dependent vasorelaxation and/or augmentation in 
endothelium-dependent vasocontraction can be the result of either a reduction in EDRF 
activity/bioavailability, an increase in EDCF activity/bioavailability, and/or a change in VSM 
sensitivity to these endothelium-derived factors (6, 15, 16). Likewise, an augmentation in 
endothelium-dependent vasorelaxation and/or attenuation in endothelium-dependent 
vasocontraction can be the result of an increase in EDRF activity/bioavailability, a reduction in 
EDCF activity/bioavailability, and/or a change in VSM sensitivity to these endothelium-derived 
factors.  
In the current study, increasing doses of SNP, an exogenous NO donor, elicited similar 
vasodilatory response curves across all groups. Likewise, increasing doses of U46619, a TP 
receptor agonist, elicited similar vasocontractile response curves across all groups. Together, 
these data suggest that neither strain nor chronic mental stress had any effect on VSM sensitivity 
to either NO or TP receptor stimulation. 
 Additionally, UCMS did not significantly affect the ratio of PE contraction in the L-
name drug condition compared to the ND condition, a putative indicator of NO effect on basal 
tone (39, 86), suggesting that UCMS did not increase NO levels. These data would suggest that 
the UCMS-induced augmentation in endothelium-dependent vasorelaxation and attenuation in 
endothelium-dependent vasocontraction might be due to a reduction in EDCF levels. As 
expected, PGI2 levels were greater in SHR compared to WKY in the L-name condition. This 
increase in PGI2 levels has been shown to contribute to the attenuation of endothelium-dependent 
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vasorelaxation in SHR compared to WKY (39, 84). Since PGI2 has been shown to be one of the 
most active prostaglandins in the WKY and SHR rat models (31, 32, 33, 37, 38, 39), it was 
originally hypothesized that PGI2 would be greater in UCMS groups compared to their 
respective controls. However, the unexpected UCMS-induced augmentation in endothelium-
dependent vasorelaxation and attenuation in endothelium-dependent vasocontraction would have 
suggested that PGI2 would instead be reduced in the UCMS groups compared to their respective 
controls. Unexpectedly, the current study demonstrated that UCMS had no effect on PGI2 levels 
in WKY and only slightly reduced PGI2 levels in SHR. It is possible that the number of animals 
in each group did not provide enough power for this reduction to reach significance. 
Alternatively, Stanley et al. found that the vascular production of COX-mediated vasoconstrictor, 
TXA2, was significantly greater in Balb/cJ mice after UCMS compared to control mice (65). 
Therefore, it is possible that UCMS has a greater effect on TXA2 levels than on PGI2 levels and 
that, if measured in the current study, a reduction in TXA2 levels may have been detected in the 
UCMS groups compared to control groups.  
 
6.1 Limitations  
 
 This thesis aimed to investigate the effects of UCMS on endothelial function in both 
hypertensive and normotensive animal models. The WKY and SHR rat strains were desirable to 
use for the current study because SHR have become the preferred animal model for studying 
hypertension (100) and WKY rats are often used as the normotensive control strain to which 
findings in SHR rats are compared against (73). As such, a significant amount of data already 
exists regarding the differences in endothelial function between the strains, and the related 
mechanisms through which these differences evolve (31, 39, 74, 75, 76). Furthermore, the effects 
of UCMS in SHR and WKY had not yet been investigated, which added to the desire to study 
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these strains in the current study. Therefore, even though it was known that WKY have been 
used in previous literature as an animal model of depression and have been shown to be hyper-
reactive to stress compared to SHR (93, 94, 95), SHR and WKY were the animal models chosen 
for this study. 
Another potential limitation to this study is how unstandardized the UCMS protocol 
remains, and as a result how much the protocol varies between investigators. Four important 
criteria should be considered when investigating the effects of chronic mental stress on 
physiological outcomes, as each one could potentially affect the physiological response. These 
criteria include (1) the duration of the intervention, (2) the time in the subject’s life when the 
intervention is being introduced (i.e., the age of the subject), (3) the intensity of each individual 
stressor, as defined not only by how powerful the stressor is but also by how long the stressor 
lasts and how frequently the stressor occurs, and (4) the mode (i.e., type) of stressor. For 
example, a study by Puzserova et al. demonstrated that endothelium-dependent vasorelaxation in 
femoral arteries from WKY was enhanced following 8 weeks of chronic stress induced by 
crowded housing (i.e., 5 animals/cage instead of 4 animals/cage) (58). However, endothelium-
dependent vasorelaxation was impaired following 12 weeks of crowded housing (58). These data 
suggest that the length (i.e., duration) of the chronic mental stress intervention can affect the 
physiological outcome. Additionally, a study by Fuchs et al. demonstrated that, following 
chronic behavioural stress, endothelium-dependent vasorelaxation was enhanced in coronary 
arteries from young (3 mo.) BHR, but was impaired in coronary arteries from old (18 mo.) BHR 
(59). These data suggest that the time during the life course at which the intervention is 
introduced (i.e., the age of the animals) can affect the physiological response(s) to the chronic 
stress. Furthermore, while no studies currently exist whereby the physiological responses to 
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varying intensities of stressors have been systematically investigated, it is logical to assume that 
the degree of physiological response will increase as the intensity of the stressor increases. 
Likewise, no studies currently exist whereby the mode (i.e., type) of stressors have been 
systematically investigated to ensure that the protocol induces the outcome of interest. For 
example, Zhu et al. demonstrated that while both the UCMS protocol and chronic restraint stress 
were sufficient to induce anxiety-like behaviours in C57BL/6 mice, only the UCMS protocol was 
sufficient to induce depressive-like behaviours, suggesting that choosing a specific mode of 
stressor is likely important in achieving a certain desired outcome (101). 
The UCMS protocol is considered to be the most validated model for studying the 
(patho)physiological outcomes of chronic mental stress (61, 62). However, the duration of the 
protocol, the optimal time to introduce the protocol, and the intensity of the stressors within the 
protocol have not yet been standardized. Previous literature has demonstrated that these criteria 
can affect the physiological outcome in response to the chronic mental stress and therefore the 
lack of standardization of the UCMS protocol was likely a limitation within this study.  
 
6.2 Future Directions 
 Chronic mental stress has been shown to be associated with CVD, and is now emerging 
as a CVD risk factor (45, 46, 52, 53, 54, 90, 91, 92). Currently, researchers are investigating the 
underlying mechanisms to explain a cause and effect relationship between chronic mental stress 
and CVD risk factors (65, 66, 67). However, since the UCMS protocol shows the most promise 
to be the most validated model for studying the effects of chronic mental stress, a logical next 
step is to establish a standardized protocol so that all investigators are using the same protocol 
and so that reliable results can be obtained and compared between studies. In order to standardize 
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the protocol, a study needs to be done wherein the physiological and behavioural responses to 
varying intensities of stressors are investigated. The intensity of the stressors within the protocol 
should aim to closely represent the type of stress that is trying to be imitated. For example, the 
mild stressors most commonly used in the UCMS protocol try to imitate the level of stress that is 
experienced in everyday life (61, 62).  
 Once the individual stressors within the UCMS protocol have been standardized, the 
effects of the duration of the UCMS protocol and the age of the animals can then be further 
investigated. This will allow investigators to develop their research questions based on the 
knowledge of how each of these factors can affect the results. Puzserova et al. demonstrated that 
chronic mental stress might improve endothelial function before leading to endothelial 
dysfunction (58). This was demonstrated by the fact that 8 weeks of chronic stress enhanced 
endothelium-dependent vasorelaxation where as 12 weeks of chronic stress impaired 
endothelium-dependent vasorelaxation (58). However, because measures were only taken at 8 
and 12 weeks, it is unknown at what time-point maximal endothelial function (i.e., maximally 
enhanced endothelium-dependent vasorelaxation) and maximal endothelial dysfunction (i.e., 
maximally impaired endothelium-dependent vasorelaxation) may have been achieved. Therefore, 
a study should be performed wherein measures are taken weekly to determine the time-course of 
the physiological effects of chronic mental stress. It would be important for this study to include 
animals of various ages since Fuchs et al. demonstrated that the physiological effects of chronic 
mental stress may be vary depending on the age of the animals being studied (59). Therefore, it 
might be hypothesized that the time-course of the physiological effects of chronic mental stress 
may also be different in animals of different ages. For example, younger animals may adapt to 
the chronic mental stress earlier than older animals and may be able to compensate for longer 
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before endothelial dysfunction develops. Unfortunately, no studies, to date, have specifically 
investigated this theory. 
 Ideally, this research will reveal how chronic mental stress can cause endothelial 
dysfunction, on a mechanistic level. Additionally, since chronic mental stress is considered one 
of the modifiable CVD risk factors people could potentially reduce their risk for CVD by 
modifying their behaviour in such a way that reduces their stress levels (45, 46, 52, 53, 54).  
Therefore, once the underlying mechanisms explaining how chronic mental stress increases an 
individual’s risk of CVD, biomarkers for monitoring one’s stress levels may be identified and the 
effect of various interventions can be tested. Similarly to how monitoring one’s blood glucose 
levels might encourage diabetics to improve their diets, as demonstrated by Ong et al., 
monitoring one’s stress levels may also encourage chronically stressed individuals to partake in 
stress-relieving activities (102). Ultimately, the objective is for researchers to use a standardized 
chronic mental stress protocol to better understand how chronic mental stress causes endothelial 
dysfunction on a mechanistic level, so that prevention and treatment strategies for chronic mental 
stress can be developed.  
 
6.3 Conclusion: 
 The data in the current study demonstrated that 6 weeks of UCMS (as defined in 4.2 
Unpredictable Chronic Mild Stress) improved endothelial function, as determined by an 
attenuation of endothelium-dependent vasocontraction and an augmentation of endothelium-
dependent vasorelaxation, in CCA from 30-40 week old WKY and SHR. In contrast, a large 
amount of data from previous studies has demonstrated that chronic mental stress impairs 
endothelium-dependent vasorelaxation. However, a wide variety of factors have been shown to 
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contribute to the physiological response to chronic mental stress, including the duration, 
intensity, and mode of the stress as well as the age and strain of the animal model being 
investigated. As such, a great deal of investigation remains to standardize a chronic mental stress 
protocol in order to identify the underlying mechanisms by which chronic mental stress can lead 
to CVD. 
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Appendix I: UCMS Protocol Schedule 
Protocol 
Day 
Time Stressor Animals 
Damp 
bedding 
Altered 
light/dark 
cycle 
Cage 
tilt 
Predator 
odour 
Predator 
sounds 
Removal 
of 
bedding 
SHR WKY 
1 7AM-10AM      ! 1,2  
10AM-2PM   !    
2PM-5PM    !   
5PM-9PM  !     
9PM-7AM   !  !  
2 7AM-10AM   ! !   1,2 1,2 
10AM-2PM      ! 
2PM-5PM     !  
5PM-9PM !   !   
9PM-7AM       
3 7AM-10AM  !     1,2,3,4 1,2 
10AM-2PM    !   
2PM-5PM    !  ! 
5PM-9PM !!      
9PM-7AM       
4 7AM-10AM    !   1,2,3,4 1,2 
10AM-2PM  !     
2PM-5PM !  !    
5PM-9PM !!  !    
9PM-7AM      ! 
5 7AM-10AM   !  !  1,2,3,4 1,2 
10AM-2PM  !    !
2PM-5PM       
5PM-9PM       
9PM-7AM    !!   
6 7AM-10AM !     ! 1,2,3,4 1,2,3,4 
10AM-2PM  !     
2PM-5PM  !     
5PM-9PM    !   
9PM-7AM      !
7 7AM-10AM     !!  1,2,3,4,5,6 1,2,3,4 
10AM-2PM       
2PM-5PM !      
5PM-9PM  !     
9PM-7AM !   !   
8 7AM-10AM       1,2,3,4,5,6 1,2,3,4,5,6 
10AM-2PM   !    
2PM-5PM  !   !  
5PM-9PM     !  
9PM-7AM   ! !   
9 7AM-10AM       1,2,3,4,5,6, 1,2,3,4,5,6 
!! %"!
10AM-2PM !    !  7,8 
2PM-5PM !      
5PM-9PM   !  !  
9PM-7AM   !    
10 7AM-10AM  !     1,2,3,4,5,6, 
7,8 
1,2,3,4,5,6, 
7,8 
10AM-2PM   !   ! 
2PM-5PM   !    
5PM-9PM     !  
9PM-7AM !      
11 7AM-10AM    !   1,2,3,4,5,6, 
7,8 
1,2,3,4,5,6, 
7,8 10AM-2PM   !  !  
2PM-5PM  !   !  
5PM-9PM      !
9PM-7AM       
12 7AM-10AM    !!   1,2,3,4,5,6, 
7,8 
1,2,3,4,5,6, 
7,8 10AM-2PM     ! !
2PM-5PM       
5PM-9PM !      
9PM-7AM  !     
13 7AM-10AM ! !     1,2,3,4,5,6, 7,8,9,10 
1,2,3,4,5,6, 
7,8 
10AM-2PM    !   
2PM-5PM     !  
5PM-9PM       
9PM-7AM   ! !   
14 7AM-10AM    !   1,2,3,4,5,6, 
7,8,9,10 
1,2,3,4,5,6, 
7,8,9,10 
10AM-2PM     !  
2PM-5PM  !  !   
5PM-9PM       
9PM-7AM   !   ! 
15 7AM-10AM  !    ! 1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10 
10AM-2PM      ! 
2PM-5PM    !   
5PM-9PM !      
9PM-7AM  !     
16 7AM-10AM  !    ! 1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM   !    
2PM-5PM    !   
5PM-9PM   !    
9PM-7AM ! !   !  
17 7AM-10AM      ! 1,2,3,4,5,6, 7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM !    !  
2PM-5PM  ! !    
5PM-9PM       
9PM-7AM      ! 
18 7AM-10AM       1,2,3,4,5,6, 1,2,3,4,5,6, 
!! %$!
10AM-2PM     !!  7,8,9,10, 
11,12 
7,8,9,10, 
11,12 2PM-5PM !  !    
5PM-9PM  !     
9PM-7AM      ! 
19 7AM-10AM !      1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 
10AM-2PM      !!
2PM-5PM    !   
5PM-9PM  !     
9PM-7AM     !  
20 7AM-10AM       1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 
10AM-2PM   !   ! 
2PM-5PM  !    !
5PM-9PM    !   
9PM-7AM    !   
21 7AM-10AM       1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 
10AM-2PM     !  
2PM-5PM      !
5PM-9PM !     ! 
9PM-7AM   !  !  
22 7AM-10AM !    !  1,2,3,4,5,6, 7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM   ! !   
2PM-5PM       
5PM-9PM  !     
9PM-7AM      ! 
23 7AM-10AM   !    1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 
10AM-2PM    ! !  
2PM-5PM      !
5PM-9PM ! !     
9PM-7AM       
24 7AM-10AM    !   1,2,3,4,5,6, 7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM   !  !  
2PM-5PM ! !     
5PM-9PM       
9PM-7AM    !   
25 7AM-10AM     !  1,2,3,4,5,6, 7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM  ! !    
2PM-5PM !   !   
5PM-9PM       
9PM-7AM     !  
26 7AM-10AM    !   1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM    !   
2PM-5PM       
5PM-9PM !  !    
9PM-7AM  !    !
27 7AM-10AM    !   1,2,3,4,5,6, 1,2,3,4,5,6, 
!! %%!
10AM-2PM   !   ! 7,8,9,10, 11,12 
7,8,9,10, 
11,12 
2PM-5PM    !   
5PM-9PM  !     
9PM-7AM     !  
28 7AM-10AM   !!    1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 
10AM-2PM  !   !  
2PM-5PM      !
5PM-9PM    !  !
9PM-7AM       
29 7AM-10AM  !!     1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 
10AM-2PM       
2PM-5PM    !   
5PM-9PM !   !   
9PM-7AM     !  
30 7AM-10AM    !   1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 
10AM-2PM       
2PM-5PM   !! !   
5PM-9PM !    !  
9PM-7AM !      
31 7AM-10AM   !  !  1,2,3,4,5,6, 7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM      !!
2PM-5PM   !    
5PM-9PM       
9PM-7AM    !   
32 7AM-10AM !     ! 1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM  !     
2PM-5PM       
5PM-9PM  !     
9PM-7AM   !   ! 
33 7AM-10AM    ! !  1,2,3,4,5,6, 7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM      !
2PM-5PM !      
5PM-9PM !      
9PM-7AM    !   
34 7AM-10AM       1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 
10AM-2PM   ! !   
2PM-5PM     ! !
5PM-9PM !      
9PM-7AM    !   
35 7AM-10AM       1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 
10AM-2PM !!      
2PM-5PM       
5PM-9PM  !   !  
9PM-7AM   !   !
36 7AM-10AM  !   !  1,2,3,4,5,6, 7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM  ! !    
!! %&!
2PM-5PM       
5PM-9PM       
9PM-7AM !   !   
37 7AM-10AM      ! 1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM !  !    
2PM-5PM     !  
5PM-9PM    !  ! 
9PM-7AM       
38 7AM-10AM    !  ! 1,2,3,4,5,6, 7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM !     ! 
2PM-5PM       
5PM-9PM !   !   
9PM-7AM       
39 7AM-10AM  !    ! 1,2,3,4,5,6, 7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM !   !   
2PM-5PM       
5PM-9PM    !   
9PM-7AM   !    
40 7AM-10AM    !  ! 1,2,3,4,5,6, 7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM !      
2PM-5PM  !     
5PM-9PM    !   
9PM-7AM   !    
 
41 7AM-10AM      ! ! 1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM !      
2PM-5PM    !   
5PM-9PM    !   
9PM-7AM  !     
42 7AM-10AM      !! 1,2,3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 
10AM-2PM !  !    
2PM-5PM       
5PM-9PM    !   
9PM-7AM     !  
43 7AM-10AM      !! 3,4,5,6, 
7,8,9,10, 
11,12 
1,2,3,4,5,6, 
7,8,9,10, 
11,12 
10AM-2PM !!      
2PM-5PM   !    
5PM-9PM    !   
9PM-7AM       
44 7AM-10AM      ! 3,4,5,6, 
7,8,9,10, 
11,12 
3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM !    !  
2PM-5PM !      
5PM-9PM  !  !   
9PM-7AM       
45 7AM-10AM      ! 5,6, 
7,8,9,10, 
11,12 
3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM !!      
2PM-5PM    !   
!! %'!
5PM-9PM    !   
9PM-7AM     !  
46 7AM-10AM      ! 5,6, 7,8,9,10, 
11,12 
3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM !  !    
2PM-5PM      ! 
5PM-9PM    !!   
9PM-7AM       
47 7AM-10AM      ! 5,6, 
7,8,9,10, 
11,12 
3,4,5,6, 
7,8,9,10, 
11,12 10AM-2PM !      
2PM-5PM      ! 
5PM-9PM !   !   
9PM-7AM     !  
48 7AM-10AM !     ! 5,6, 
7,8,9,10, 
11,12 
5,6, 
7,8,9,10, 
11,12 10AM-2PM !   !   
2PM-5PM       
5PM-9PM  !  !   
9PM-7AM       
49 7AM-10AM      ! 7,8,9,10, 11,12 
5,6, 
7,8,9,10, 
11,12 10AM-2PM !   !   
2PM-5PM      ! 
5PM-9PM  !  !   
9PM-7AM       
50 7AM-10AM    !  ! 7,8,9,10, 11,12 
7,8,9,10, 
11,12 
10AM-2PM !    !  
2PM-5PM  !     
5PM-9PM    !   
9PM-7AM       
51 7AM-10AM     ! ! 9,10,11,12 7,8,9,10, 11,12 
10AM-2PM ! !     
2PM-5PM !      
5PM-9PM    !   
9PM-7AM       
52 7AM-10AM    !  ! 9,10,11,12 9,10,11,12 
10AM-2PM !      
2PM-5PM       
5PM-9PM   ! !   
9PM-7AM      ! 
53 7AM-10AM   !   ! 9,10,11,12 9,10,11,12 
10AM-2PM !     ! 
2PM-5PM       
5PM-9PM  !  !   
9PM-7AM       
54 7AM-10AM   !   ! 9,10,11,12 9,10,11,12 
10AM-2PM !      
2PM-5PM  !     
5PM-9PM    !  ! 
!! &(!
9PM-7AM       
55 7AM-10AM  !    ! 11,12 9,10,11,12 
10AM-2PM !      
2PM-5PM       
5PM-9PM    !!   
9PM-7AM     !  
56 7AM-10AM      ! 11,12 11,12 
10AM-2PM !      
2PM-5PM    !   
5PM-9PM    ! !  
9PM-7AM !      
57 7AM-10AM     ! ! ! 11,12!
10AM-2PM !     ! 
2PM-5PM   !    
5PM-9PM    !   
9PM-7AM       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
